References
- Ahmed, Z., Fraser, W, Kerr, M.P., Kiernan, C., Emerson, E., Robertson, J., Felce, D., Allen, D. and Baxter, H. (2000). Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry, 176,42–46.
- British Medical Association and Royal Pharmaceutical Society of Great Britain. (2008). British National Formulary (56th edition). London & Wallingford: BMJ Books & Pharmaceutical Press.
- Brylewslci, J. and Duggan, L. (2004). Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database of Systematic Reviews Issue 3. Art. No.: CD000377. DOI:10.1002/14651858.CD000377.pub2
- Centorrino, E, Goren J.L., Hennen, J., Salvatore, P., Kelleher, J.P. and Baldessarini, R.J. (2004). Multiple versus single antipsychotic agents for hospitalised psychiatric patients: case-control study of risks versus benefits. American Journal of Psychiatry, 161, 700–706.
- Cooray, S.E. and Tolmac, J. (1998). Antipsychotic medication in learning disability: Impact of audit and evidence-based medicine on quality of prescribing in a community assessment treatment unit. The Psychiatrist, 22, 601–604.
- Dalvi, M., Thalayasingam, S.P. and George, G.R. (2003). Audit on high dose antipsychotic medication in three tertiary services for people with learning disability. British Journal of Developmental Disabilities, 49, 117–124.
- Davies, S.J., Lennard, M.S., Ghahramani, P., Pratt, P., Robertson, A. and Potokar, J. (2007). PRN prescribing in psychiatric inpatients - potential for pharmacokinetic drug interactions. Journal of Psychopharmacology, 21, 153–160.
- Geffen, J., Sorensen, L., Stokes, J., Cameron, A., Roberts, M.S. and Geffen, L. (2002). Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals. Australian and New Zealand Journal of Psychiatry, 36, 649–656.
- Lelliott, P., Paton, C., Harrington, M., Konsolalci, M., Senlcy, T. and Okocha, C. (2002). The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. The Psychiatrist, 26,411–414.
- Procyshyn, R.M., Kennedy, N.B., Tse, G. and Thompson, B. (2001). Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatry institution. Canadian Journal of Psychiatry, 46, 334–339.
- Royal College of Psychiatrists (2006). Consensus Statement on High Dose Antipsychotic Medication (Council Report CR138).
- Royal College of Psychiatrists (2001). Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/Mental Retardation (DCLD), London. Gaskell Press.
- Silifant, K., Muir, J., Read, S. and Crabb, M. (1997). Monitoring of patients on high dose antipsychotic medication. The Psychiatrist, 21, 612–614.
- Sovner, R. (1989). Treating mentally retarded adults with psychotropic drugs: a clinical perspective. In Mental Retardation and Mental Illness. 157–183. Lexington. MA: Lexington Books.
- Szczesny, S. and Miller, M. (2003). PRN medication in inpatient psychiatry. Journal of Psychosocial Nursing & Mental Health Services, 41, 16–21.
- Whicher, E., Morrison, M. and Douglas-Hall, P (2002). 'As required' medication regimens for seriously mentally ill people in hospital (review). Cochrane Database of Systematic Reviews, issue 3, CD 003441.
- Yorston G and Pinney A. (2000). Chlorpromazine equivalents and percentage of British National Formulary maximum recom-mended dose in patients receiving high-dose antipsychotics. The Psychiatrist, 24, 130–132.